Longevity Industry in Switzerland:
Landscape Overview 2019

Longevity in Switzerland (2).png

Aging Analytics Agency’s “Longevity Industry in Switzerland: Landscape Overview 2019” report delivers a comprehensive overview of the history, present state and near-future trajectory of the Switzerland Longevity Industry, profiling its key players, including 100 leading companies, 80 investors, 50 financial corporations, 15 influencers, 35 research labs, 20 P4 clinics, 15 non-profit, 15 governmental organizations 10 journals, 15 scientists and 15 journalists active in the Swiss Longevity sphere. The report is accompanied by the launch of an online IT platform that transforms the static data and graphics featured in the report into interactive mindmaps, enabling the complex interactions between industry entities and stakeholders in the region to be visualized, filtered, searched and thus more easily understood.


The choice of Switzerland as the subject of Aging Analytics Agency’s regional Longevity industry report series is justified for a number of reasons. Switzerland is thought to be second only to Japan in terms of the number of people who have reached 100 (Switzerland has the highest life expectancy in Europe at 83.7 years, according to Eurostat). According to the study conducted by the Institute for Social and Preventive Medicine, about 40 out of every 10,000 people born in 1900 in Switzerland made it to their 100th birthday. Life expectancy has increased by 98 per cent for men and 96 per cent for women in the past century and a half.


Switzerland is an international center of finance where investment banks are acutely aware of the demographic challenge and the incentives to do something about it. The financial sector ensures that the Swiss economy is never short of the necessary capital or financial services. Switzerland has been leading transformative developments emerging from the digitalization of its banking and financial sector. Even the Swiss Board of Advisors name now digitization as the most important topic. Switzerland is also one of the most efficiently regulated and supervised financial centers in the world today.


Switzerland is known to be one of the most longevity-progressive countries, which defines it not simply as country with high investment in biotechnology, but those one most capable of integrating AI into its economic, financial, and healthcare systems. Switzerland spends the highest percentage of GDP on healthcare (around 11.4 percent) compared to all EU countries. Basic health insurance is compulsory in Switzerland, although you are free to choose your own Swiss health insurance company. In the EU’s latest statistics, Switzerland was the only country compared to the EU to total more than EUR 4,500 per inhabitant on healthcare expenditure. Healthcare is largely organised by Switzerland’s individual communes. The health ministers from all cantons form the Swiss Conference of the Cantonal Ministers of Public Health (GDK), which aims to promote cooperation and implement common policies between cantons. 


The report is structured so as to introduce readers to the key developments in the  Swiss Longevity field as well as offers a global perspective on the topic. By utilizing a variety of infographic mind maps, the report first enables the audience to quickly identify its core analytical findings and conclusions. Its chapter sequence then introduces readers to specific areas of the Longevity industry in Switzerland by highlighting pertinent scientific and technological trends, providing an overview of underlying demographic and economic data as well as by analyzing existing and projected governmental policies, among other issues.   The report’s appendices offer detailed information regarding companies, investors, influencers, research institutions, government entities, non-profit organizations and other principal participants in Swiss Longevity field.